Lisata Therapeutics Inc
LSTA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.9M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $10.90 Million |
|---|---|
| Enterprise Value | $-271,813,763.00 |
| Earnings per Share | $-1.91 |
| Beta | 0.8 |
| Outstanding Shares | 9,305,000 |
Return
| Return on Equity | -224.51% |
|---|---|
| Return on Assets | -2.65% |
| Return on Invested Capital | -0.79% |
Valuation & Multiples
| P/E Ratio | -0.64 |
|---|---|
| PEG | -1.08 |
| Price to Sales | - |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | -2718.14 |
| Enterprise Value to EBIT | 55 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 13, 2026
EPS
-$0.73
Est. -$1.13Revenue Estimate
$659,000
Consensus analyst estimateNext Earnings Call
Expected Date
February 26, 2027
EPS Estimate
-$2.17
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.49%▼ 11.78% |
|---|---|
| Total Invested | $195,625▼ 95.24% |
| Investors Holding | 5▼ 26.00% |
About Lisata Therapeutics Inc
24 employees
CEO: David Mazzo
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mec...